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The development of molecular biomarkers (BMs) of follicular thyroid carcinoma is aimed at advancing diagnosis of follicular
neoplasm, as histological examination of those tumors does not lend itself to deﬁnitive diagnosis of carcinoma. We assessed
the relative levels of expression of 6 genes: C C N D 2 ,P C S K 2 ,P L A B ,R A P 2 A ,T S H R ,a n dI G F - 1 Rin archived thyroid tissue. The
quantitative real-time PCR analysis revealed a signiﬁcant change in 3 genes: PSCK2 (a 22.4-fold decrease, P = 2.81E − 2), PLAB
(an 8.3-fold increase, P = 9.81E − 12), and RAP2A (a 6.3-fold increase, P = 9.13E − 10) in carcinoma compared with adenoma.
Expression of PCSK2 was equally low, PLAB was equally high, whereas RAP2A expression was signiﬁcantly higher (25.9-fold,
P = 0.039) in microdissected carcinoma cells that have invaded through the thyroid capsule and entered blood vessels than in
thyroid tumorcells growingunder the capsule.Thus,RAP2A appeared asa unique andworthy offurther evaluationcandidate BM
associated with invasion of thyroid follicular cells.
1.Introduction
Diﬀerentiated thyroid carcinomas originating from the fol-
licularepitheliumhaveapapillary(range,65–88%)andafol-
licular(range, 9–23%)histotype [1].Althoughfollicularthy-
roid carcinomas (FTCs) are the second most common diﬀer-
entiated thyroid cancers, they are more aggressive than pap-
illary thyroid carcinomas (PTCs) and invade into the capsule
(minimally invasive) and veins (angioinvasive) within the
thyroid gland. Importantly, mortality is related to the degree
ofinvasion [2].Furthermore, FTChas agreaterrate ofrecur-
rence and is frequently associated with distant metastasis to
t h el u n g ,b o n e ,b r a i n ,a n dl i v e r[ 3, 4]. Total thyroidectomy
represents the dominant method of surgical treatment for
follicular neoplasms diagnosed preoperatively by ﬁne needle
aspirates (FNAs). Distinguishing follicular adenoma from
minimally invasive or encapsulated angioinvasive carcinoma
inFNAcanbe extremely challenging [3, 5]. Gene and micro-
RNA (miRNA) expression proﬁling are being investigated to
identifypotentialBMsdiﬀerentiatingbenignfrommalignant
follicular tumors [6, 7]. Such BMs might be clinically useful
to help predicting follicular thyroid malignancy and reduce
the frequency of surgical procedures by identifying those pa-
tients with benign lesions who do not require surgical ex-
cision. So far, however, global genetic screens have not
improved preoperative diagnosis of FTC. Hence, novel ap-
proaches are necessary to identify potential preoperative
molecular BMs to facilitate the diagnosis of FTC. One of the
approaches could be discovering speciﬁc molecular BMs
associated with invasion of thyroid follicular cells.
2.Materialsand Methods
2.1. Thyroid Tissue. Cases of follicular-patterned thyroid
cancer are quite rare; even lesser is the number of remaining
samples availableforresearch. Forthisstudy,auniquecohort
of patients diagnosed with follicular-patterned thyroid can-
cerwasidentiﬁedonreviewofmedicalrecordsfromtheHos-
pital of University of Pennsylvania between 1992 and 2007.2 Journal of Thyroid Research
After reexamination of 16 available formalin-ﬁxed, paraﬃn-
embedded (FFPE) tissues (for histological presence of vas-
cular and/or capsular invasion) and initial determination of
integrityoftotalRNAinthetissuescrapes, wefoundthattwo
sampleshaddegradedRNA,onesamplehadtoolittleRNAto
be ampliﬁed by in vitro transcription (IVT), in two samples
the areas of invasion had already been cut through, and 10
specimens fully met study’s criteria. Subsequently, the study
was performed in specimens from 8 patients diagnosed with
FTC, 1 patient diagnosed with FTC-H¨ urthle cell carcinoma
(HCC), 1 patient diagnosed with HCC, and 10 patients
diagnosed with follicular thyroid adenoma (FTA). Groups
of patients with FTA (mean age, 52.4 ± 16.2SD years) and
follicular thyroid malignancy (mean age, 50.8 ± 13.1SD,
years) were age matched (Table 1). Ten normal FFPE thyroid
samples were from patients who underwent surgery after
diagnosis of larynx squamous cell carcinoma (mean age,
62.4 ± 7.0SD, years). Histopathological analysis of all tissues
was performed by a surgical pathology fellow (JG) and con-
ﬁrmed by a thyroid pathologist (Dr. Virginia LiVolsi). The
study protocol was approved by the University of Pennsylva-
nia Institutional Review Board committee.
2.2.Thyroid Tissue Analysis: RNA Extraction,cDNA Synthesis,
and Quantitative Real-Time PCR (Q-RT-PCR). RNAwasex-
tracted from the normal, adenoma, and cancer tissue scrapes
using the Absolutely RNA FFPE kit (Stratagene, La Jolla,
CA). In addition, RNA was extracted from a snap frozen
thyroid carcinoma using the High Pure RNA Tissue kit
(Roche Diagnostics, Indianapolis, IN) to use as a positive
controlandgeneratea standard curveforall subsequentPCR
reactions. Integrity of RNA from a snap frozen tissue was
determined by 260 to 280nm ratio using a DU 640 spec-
trophotometer (Beckman Coulter, Fullerton, CA). Integrity
of the scraped tissue RNA was assessed by Q-RT-PCR
using 3 ACTB and 5 ACTB primers (Table 2)a n dt h e
Paradise Sample Quality Assessment Kit (Molecular Devices,
Sunnyvale, CA). 10–100ng of the scraped tissue RNA or
500ng of a positive control RNA were reverse-transcribed
into single-stranded cDNA using the ﬁrst-strand cDNA
synthesis kit (Roche Diagnostics, Indianapolis, IN). cDNA
synthesis was carried out in a 20µL reaction mix containing
5mMMgCl 2, 1mMdNTPs, 0.04 units of random primers
p(dN)6, 50 units of RNase inhibitor, and 20 units of Avian
Myeloblastosis Virus (AMV) reverse transcriptase. Q-RT-
PCR was performed using 3µLo ft h eﬁ r s t - s t r a n dc D N A
with 1µM of the housekeeping gene, ACTB, or target gene-
speciﬁc primers (Table 2) using the LightCycler 2.0 (Roche
Molecular Biochemicals, Mannheim, Germany) instrument
and the LightCycler Fast Start DNA MasterPLUS SYBR Green
1kit (Roche Diagnostics, Indianapolis, IN) according to
the manufacturer’s instructions. PCR parameters were a
10min preincubation time at 95◦C followed by 45 cycles of
denaturation (10sec at 95◦C), annealing (10sec at 55◦C),
and extension (25sec at 72◦C). A standard curve for each
of the target and housekeeping gene was generated for every
PCR run to determine levelsofgene expression. All reactions
were performed in duplicates with at least three repeats.
Relative expression of each target gene in all samples was
determined as a ratio of mRNA of target gene to mRNA of
the housekeeping gene as described in [8].
2.3. Laser-Capture Microdissection (LCM). LCM was per-
formed as in the frozen thyroid tissue samples [9]w i t hm o d -
iﬁcations. Brieﬂy, FFPE blocks of FTC were cut into 7µm
thick sections, mounted on RNase-free membrane slides
(MMI, Manchester, NH), deparaﬃnated with d-limonene,
rehydrated with sequential washes of 100%, 95%, and 75%
ethanol, and then washed in nuclease-free water. Next,
slides were stained with Paradise staining solution (Arcturus
Engineering Inc.,MountainView, CA),dehydratedinXylene
for a minimum of 5min, and air dried. Cells from areas
of angioinvasion, capsular invasion, and tumor under the
capsule were dissected onto Capsure HS LCM Caps (MMI,
Manchester, NH) using a Laser Capture Micro-dissection
microscope Nikon ECLIPSE TE 2000-S and MMI Cell Tools
software (MMI, Manchester, NH).
2.4. Dissected Thyroid Cancer Cell Analysis: RNA Extraction
and Ampliﬁcation, cDNA Synthesis, and Q-RT-PCR. RNA
was extracted from laser-captured microdissected cancer
cellsusing theAbsolutelyRNAFFPEkit (Stratagene,La Jolla,
CA). Assessment of the integrity of cellular RNA was per-
formed by Q-RT-PCR using 3 ACTB and 5 ACTB primers.
Ampliﬁcation of RNA from laser-captured microdissected
cellswasperformed using theAmbionMessageAmp IIaRNA
kit (Ambion, Austin, TX). We used the IVT method which is
basedonthelinearampliﬁcationprotocoldevelopedandval-
idatedpreviously[10,11].Theadvantage ofsuchatechnique
is that the productof the reaction is unable to act as template
and the yield of any individual species within a mixed
population is for the most part determined by the template
concentration that is not changed. Ampliﬁcation was linear
when atleast 1ng ofLCM RNAwas used as the inputfor IVT.
Two rounds of linear ampliﬁcation of the mRNA fraction
of at least 1ng total cellular RNA were performed. First-
strand cDNA synthesis yielded cDNA incorporating a T-7
promoter sequence. This cDNA was converted to a double-
stranded transcription templateby a second-strand synthesis
reaction utilizing exogenous primers that yielded double-
stranded cDNA. Double-stranded cDNA was then used as
a template for IVT with T7 RNA polymerase to generate
ampliﬁed antisense RNA(aRNA).Integrity ofaRNAsamples
was determined as described above. aRNA samples with a
3 ACTB to 5 ACTB ratio of ≤20 or a 260 to 280nm ratio
between 1.8 and 2.2 were used for further experiments. 10–
100ng of aRNA was converted to cDNA using 1µMt a r g e t
gene-speciﬁc primers and the ﬁrst-strand cDNA synthesis
kit (Roche Diagnostics, Indianapolis, IN). Q-RT-PCR was
then performed for the housekeeping gene, ACTB,a n d
target genes as described above. After all the reactions were
performed in duplicates with at least three repeats, relative
expression of target genes was determined.
2.5. Statistical Analysis. Data were reported as mean ±
standard error of the mean (SEM). Comparisons betweenJournal of Thyroid Research 3
Table 1: Clinical data of patients from whom folliculart h y r o i dt u m o rt i s s u es a m p l e sw e r ec o l l e c t e d .
Gender Age, years FNA diagnosis Nodule size, cm Final diagnosis Invasion vascular/capsular
F 48 Follicular neoplasm 5.6 × 4.0 × 2.4 FTC +/+
M6 4 N A N A F T C + / +
F 51 Follicular neoplasm 2.0 × 1.5 × 1.0 FTC +/+
F 48 Follicular neoplasm 3.6 × 3.0 × 2.2 FTC +/+
F5 6 N A N A F T C + / +
M2 5 N A N A F T C + / +
F 40 Follicular neoplasm 3.0 × 2.5 × 1.5 FTC +/+
F 59 Follicular neoplasm 3.8 ×1.8 × 1.7 HCC,
angioinvasive +/+
M 45 Follicular neoplasm 3.8 × 3.1 × 2.5 FTC +/+
M7 2 B e n i g n g o i t e r 7 . 0 × 5.3 × 4.3 FTC and HCC −/+
M 45 Follicular neoplasm 3.2 × 3.0 × 3.0 FTA −/−
M 76 Follicular neoplasm 3.1 × 5.3 × 2.6 FTA −/−
M 41 Follicular neoplasm 3.1 × 2.1 × 1.7 FTA −/−
F 76 Follicular neoplasm 3.1 × 2.0 × 1.5 FTA −/−
M 64 Follicular neoplasm 4.5 × 4.4 × 3.3 FTA −/−
M6 0 N A3 . 8 × 3.0 × 5.0 FTA −/−
F 28 Follicular neoplasm 2.5 × 2.2 × 2.0 FTA −/−
F 52 Follicular neoplasm 5.0 × 4.0 × 3.5 FTA −/−
F 44 Follicular neoplasm 4.5 × 3.5 × 2.9 FTA −/−
F 38 Follicular neoplasm 3.1 × 1.9 × 1.5 FTA −/−
N/A: records were not available.
Table 2: A list of tested genes and encoded by them proteins, including the gene and protein accession numbers and corresponding intron-
spanning primers used for Q-RT-PCR.
Gene GenBank Primer sequence Protein Swiss-Prot
CCND-2 AY888219 S CAC TTG TGA TGC CCT GAC TG G1/S-speciﬁc cyclin-D2 P30279
AS ACG GTA CTG CTG CAG GCT AT
PCSK2 BC040546 S AGC ATA CAA CTC CAA GGT TGC Proprotein convertase subtilisin/kexin type 2 Q8IWA8
AS G C TG T AG A TG T CA A TC A GC T GT G
PLAB BC008962 S CAA CCA GAG CTG GGA AGA TT Placental bone morphogenetic protein Q99988
AS AGA GAT ACG CAG GTG CAG GT
RAP2A NM 021033 S AGA TCA TCC GCG TGA AGC Ras-related protein-2a P10114
AS CCC CAC TCT TCA GCA AGG
TSHR BC024205 S GGA TAT GCT TTC AAT GGG ACA Thyroid-stimulating hormonereceptor P16473
AS GCA TCT TTG TCA ATA ACT GTC AGG
IGF1R NM000875 S GTG AAA GTG ACG TCC TGC ATT TC Insulin-like growth factor I receptor P08069
AS CCT TGT AGT AAA CGG TGA AGC TGA
3 ACTB NP001092 S TCC CCC AAC TTG AGA TGT ATG AAG Actin, cytoplasmic 1 P60709
AS AAC TGG TCT CAA GTC AGT GTA CAG G
5 ACTB NP001092 S ATC CCC CAA AGT TCA CAA TG Actin, cytoplasmic 1 P60709
AS G T GG C TT T TA G GA T GG C AA G
S: sense, forward primer5  to 3 ; AS: antisense, backword primer 3  to 5 .4 Journal of Thyroid Research
normal, benign, and cancer groups were made by using one-
way analysis of variance (ANOVA). A value of P<. 05 was
considered as statistically signiﬁcant.
3.Resultsand Discussion
In this exploratory study, we investigated the expression of
the potential thyroid cancer-discriminating genes: CCND2,
PCSK2,PLAB, RAP2A, TSHR,a n dIGF-1R (Table 2)b yc om -
paring their expression at the mRNA levels in the normal
thyroid tissue, benign follicular lesions, and follicular carci-
nomas. The target genes have been chosen based on impor-
tance of abnormal expression and activities of the thyroid-
stimulating hormone receptor (TSHR) and insulin- like
growth factor type I receptor (IGF-IR) in thyroid tumori-
genesis [12, 13] and the results of gene micro-array analysis
showing diﬀerential expression of CCND2, PCSK2, PLAB,
RAP2A in FTC [14, 15]. We found no statistically signiﬁcant
diﬀerence in CCND2, TSHR,a n dIGF-1R mRNA expression
between the groups of normal thyroid, benign and malig-
nant thyroid cancer (Figure 1(a)). There was no diﬀerence
between the levels of mRNA expression of PCSK2, PLAB,
and RAP2A between normal thyroid and FTA (Figure 1(b)).
Interestingly, however, in the Q-RT-PCR analysis of FTA
and cancer, PSCK2was markedly downregulated (22.4-fold),
whereas PLAB and RAP2A were notably upregulated (8.3-
and 6.3-fold, resp.) in cancer. Furthermore, a comparative
mRNA expression analysis revealed a statistically signiﬁcant
diﬀerencein PCSK2(P = 2.81E−2), PLAB(P = 9.81E−12)
and RAP2A (P = 9.13E − 10) expression between groups of
benign and malignant thyroid tumors (Figure 1(b)). Thus,
in tested age-matched cohort of 20 patients diagnosed with
follicular-patterned thyroid neoplasm, the levels of CCND2,
TSHR,a n dIGF-1R were not signiﬁcantly diﬀerent; PLAB
and RAP2A were signiﬁcantly increased, whereas PCSK2was
signiﬁcantly decreased in cancer compared with adenoma.
Overexpression of PLAB and PCSK2 as well as down-
regulation of CCND2 has been found in frozen sections of
FTC [15]. Weber et al. proposed that a combination of those
three genes allowed the accurate molecular classiﬁcation
of FTC versus FTA with a high speciﬁcity and sensitivity.
However, Shibru et al. were unable to conﬁrm the diagnostic
accuracyofthe3-geneassay eitherinfrozen tissueorinFNAs
[16]. The diﬀerence is likely attributed to the diﬀerence in
types of analyzed tissue, as Shibru et al. compared a benign
group represented by hyperplastic nodule, FTA, H¨ urthle
cell adenomas (HCAs) with a collective group of thyroid
malignancies, including FTC, PTC, follicular variant of
PTC, HCC. Although FTC and HCC may carry similar
molecular alterations [17], PTC has distinct genetic features
(somatic alterations such as RET/PTC translocation and
BRAF mutations) that distinguish them from FTC [6]. Our
data are in close agreement with the ﬁndings reported by
Weber et al. except that the observed down-regulation of
CCND2 in cancer has not reached statistical signiﬁcance.
Intratumoral heterogeneity is well-recognized phenome-
non [5, 18, 19], so it is plausible that within areas of invasion






































































Figure 1: Evaluation of CCND2, TSHR, IGF-1R (a) and PCSK2,
PLAB, RAP2A (b) mRNA expression by Q-RT-PCR in tissue sam-
ples from the human thyroid (normal, benign, cancer). All PCR
reactions were performed in duplicates with at least three repeats.
Mean of normalized expression level of mRNA in each analyzed
group (n = 10) are shown. Bar, SEM. ∗P = 2.81E − 2, ∗∗P =
9.81E − 12, and ∗∗∗P = 9.13E −10.
Here, we tested the hypothesis that in thyroid malignancy
diﬀerential expression of molecular BMs may be detected
in thyroid follicular cancer cells invaded through the tumor
capsule and entered into vasculature. The three genes
(PCSK2, PLAB,a n dRAP2A) were selected for in-depth
analysis because of their signiﬁcantly diﬀerent expression in
cancers compared with adenomas (Figure 1(b)). To ensure
t h ep r e s e n c eo fi n v a s i o ni nf r e s h l yc u t7µm thick sections of
cancer tissue, a thyroid pathologist reviewed slides stained
with hematoxylinandeosin andmarkedtheareasofinvasion
using diagnostic criteria adopted in our institution [3]. Nine
angioinvasive samples of thyroid cancers had both capsular
and vascular invasion; one minimally invasive specimen had
only capsular invasion. Eight out of ten specimens had more
than one invasive focus. To selectively isolate population of
thyroidcarcinomacellsthathaveinvadedthecapsuletoenter
blood vessels and to compare them to the cells remained
in the main tumor mass, we applied an LCM method as
illustrated in Figure 2(a). After dissecting multiple areas,
the captured cells from each of the cancer specimens were
pooled in to two matched groups: (i) remained under the
tumor capsule (“noninvasive” group) and (ii) invaded the
capsule and/or entered blood vessels (“invasive” group). The
total RNA was assessed in the captured tumor cells, and







































thyroid carcinoma. (a) FTC tissue before (left) and after collecting
thegroups ofcells fromthemaintumormass(inset1)andangioin-
vasive area (inset 2). Original magniﬁcation, 200x. (b) Histogram,
relative expression of PCSK2, PLAB, RAP2A in the cells collected
frommatchednoninvasiveandinvasiveareasofthesamespecimens
(n = 4). Mean of normalized expression levels of aRNA in each
group is shown. Bar, SEM. ∗P = 0.039.
were subjected to two rounds of linear ampliﬁcation by in
vitro transcription to further increase the amount of RNA.
Twice-ampliﬁed aRNA of high quality only was used for
a cDNA preparation and Q-RT-PCR with speciﬁc primers
for target genes. As expected from the analysis of tissue
scrapes, PSCK2 expression was low in the cells from the
main tumor mass; it was insigniﬁcantly diﬀerent (P =
0.322) in invasive cells dissected from the same specimens
(Figure 2(b)). Likewise, PLAB expression was equally high
in both types of dissected cells (P = 0.698). The results of
the Q-RT-PCR analysis for RAP2A aRNA were intriguing, as
the relative level of RAP2A expression was 25.9-fold higher
(P = 0.039) in the cells dissected from areas of inva-
sion. RAP2A encodes Ras-related protein 2a (Rap-2a), a
member of the Ras family of small GTPases (Rap1a/b and
Rap2a/b/c) that has been reported to induce cytoskeleton
rearrangements promoting cell rounding and cell migration
[20, 21]. Although activating mutations of Rap have not
been reported, up regulation of Rap activating guanine
nucleotide exchange factors [22, 23] and down regulation of
Rap GTPase-activating proteins promoting Rap inactivation
[24,25]havebeenfoundinhumantumorsincludingthyroid
carcinomas [26]. High levels of expression of Rap2, but not
Rap1, have been detected in human thyroid cancer cell lines.
Importantly, Rap2 protein expression was several fold higher
in anaplastic than in well-diﬀerentiated papillary thyroid
cancer cells [27]. Furthermore, increased Rap activity has
been shown to promote carcinoma cells invasion in vitro
and in vivo [28, 29]. We found up regulation of human
gene encoding Rap-2a in follicular thyroid cancer tissue,
particularly intheregionsenriched withinvasivecancercells.
It could be speculated that thyroid tumor cells “require” the
genetic changes in RAP2A, in addition to PSCK2 and PLAB,
to allow them to invade and/or “maintain and ﬂourish” in
the nonnative areas of the tumor capsule and blood vessels.
4.Conclusions
We demonstrated the feasibility of combining LCM and Q-
RT-PCR for analysis of gene expression in microscopic clus-
ters dissected from FFPE thyroid tissue. Our study is a ﬁrst
and important step in the assessment of novel molecular
BMs associated with invasion of follicular thyroid carcinoma
cells, despite the relatively small sample size. Validation of
diagnostic applicability of RAP2A requires a follow-up work
in larger tissue sample sets.
Conﬂictof Interests
The authors declare that they have no competing interests.
Acknowledgments
The authors are extremely grateful to Dr. Virginia LiVolsi
for reviewing clinical samples of follicular thyroid tumors
and providing critical comments on the paper. They also
thank members of the Eastern Division of the Cooperative
Human Tissue Network for providing frozen samples of the
thyroid and members of the Gastrointestinal Morphology
Core at the University of Pennsylvania for sharing with us
a laser-capture micro-dissection work station. Special thanks
to Theresa Pasha for excellent technical support. J. R. Grau,
current address: Lehigh Valley Health Network, Department
of Pathology and Laboratory Medicine, Cedar Crest & I-78,
P.O. Box 689, Allentown, Pennsylvania 18105-1556.
References
[ 1 ]L .E n e w o l d ,K .Z h u ,E .R o ne ta l . ,“ R i s i n gt h y r o i dc a n c e r
incidence in the United States by demographic and tumor
characteristics, 1980–2005,” Cancer Epidemiology Biomarkers
and Prevention, vol. 18, no. 3, pp. 784–791, 2009.
[ 2 ]C .Y .L o ,W .F .C h a n ,K .Y .L a m ,a n dK .Y .W a n ,“ F o l l i c u l a r
thyroid carcinoma: the role of histology and staging systems
in predicting survival,” Annals of Surgery, vol. 242, no. 5, pp.
708–715, 2005.
[3] Z. W. Baloch and V. A. LiVolsi, “Our approach to follicular-
patterned lesions of the thyroid,” Journal of Clinical Pathology,
vol. 60, no. 3, pp. 244–250, 2007.
[4] R. L. Witt, “Initial surgical management of thyroid cancer,”
Surgical Oncology Clinics of North America, vol. 17, no. 1, pp.
71–91, 2008.6 Journal of Thyroid Research
[5] J.L. Hunt, V. A. Livolsi,Z. W. Baloch et al.,“A novel microdis-
section andgenotypingoffollicular-derived thyroidtumorsto
predict aggressiveness,” Human Pathology,v o l .3 4 ,n o .4 ,p p .
375–380, 2003.
[ 6 ]M .E s z l i n g e r ,K .K r o h n ,S .H a u p t m a n n ,H .D r a l l e ,T .J .G i o r -
dano, and R. Paschke, “Perspectives for improved and more
accurate classiﬁcation of thyroid epithelial tumors,” Journal
of Clinical Endocrinology and Metabolism,v o l .9 3 ,n o .9 ,p p .
3286–3294, 2008.
[7] F. Weber, R. E. Teresi, C. E. Broelsch, A. Frilling, and C. Eng,
“A limited setof humanMicroRNA Is deregulated in follicular
thyroid carcinoma,” Journal of Clinical Endocrinology and
Metabolism, vol. 91, no. 9, pp. 3584–3591, 2006.
[8] J. Becker, P. Schmidt, F. Musshoﬀ,M .F i t z e n r e i t e r ,a n dB .
Madea, “MOR1 receptor mRNA expression in human brains
of drug-related fatalities—a real-time PCR quantiﬁcation,”
Forensic Science International, vol. 140, no. 1, pp. 13–20, 2004.
[9] K. Kaserer, V. Knezevic, B. Pichlh¨ ofer et al., “Construction
of cDNA libraries from microdissected benign and malignant
thyroid tissue,” Laboratory Investigation, vol. 82, no. 12, pp.
1707–1714, 2002.
[ 1 0 ]R .N .V a nG e l d e r ,M .E .V o nZ a s t r o w ,A .Y o o l ,W .C .D e m e n t ,
J.D. Barchas,and J.H. Eberwine, “Ampliﬁed RNA synthesized
from limited quantities of heterogeneous cDNA,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 87, no. 5, pp. 1663–1667, 1990.
[ 1 1 ]H .Z h a o ,T .H a s t i e ,M .L .W h i t ﬁ e l d ,A .L .B ø r r e s e n - D a l e ,a n d
S. S. Jeﬀrey, “Optimization and evaluation of T7 based RNA
linear ampliﬁcation protocols for cDNA microarray analysis,”
BMC Genomics,vol. 3, article 31, 2002.
[12] A.Ciampolillo,C.DeTullio,E.Perlino,andE.Maiorano,“The
IGF-I axis in thyroid carcinoma,” Current Pharmaceutical
Design, vol. 13, no. 7, pp. 729–735, 2007.
[13] C. Garc´ ıa-Jim´ enez and P. Santisteban, “TSH signalling and
cancer,” Arquivos Brasileiros de Endocrinologia e Metabologia,
vol. 51, no. 5, pp. 654–671, 2007.
[14] S. Chevillard, N. Ugolin, P. Vielh et al., “Gene expression pro-
ﬁling of diﬀerentiated thyroid neoplasms: diagnostic and
clinical implications,”Clinical Cancer Research,vol. 10, no. 19,
pp. 6586–6597, 2004.
[15] F. Weber, L. Shen, M. A. Aldred et al., “Genetic classiﬁcation
of benign and malignant thyroid follicular neoplasia based on
a three-gene combination,” Journal of Clinical Endocrinology
and Metabolism, vol. 90, no. 5, pp. 2512–2521, 2005.
[16] D. Shibru, J. Hwang, E. Khanafshar, Q. Y. Duh, O. H. Clark,
and E. Kebebew, “Does the 3-gene diagnostic assay accurately
distinguish benign from malignant thyroid neoplasms?” Can-
cer, vol. 113, no. 5, pp. 930–935, 2008.
[17] F. Weber, M. A. Aldred, C. D. Morrison et al., “Silencing
of the maternally imprinted tumor suppressor ARHI con-
tributes tofollicularthyroidcarcinogenesis,”JournalofClinical
Endocrinology and Metabolism, vol. 90, no. 2, pp. 1149–1155,
2005.
[18] S. Gl¨ ockner, H. Buurman, W. Kleeberger, U. Lehmann, and
H. Kreipe, “Marked intratumoral heterogeneity of c-myc and
cyclinD1 but not of c-erbB2 ampliﬁcation in breast cancer,”
Laboratory Investigation, vol. 82, no. 10, pp. 1419–1426, 2002.
[19] S. M. Wiseman, T. R. Loree, W. L. Hicks et al., “Anaplastic
thyroid cancer evolved from papillary carcinoma: demon-
stration of anaplastic transformation by means of the inter-
simple sequence repeat polymerase chain reaction,” Archives
of Otolaryngology—Head and Neck Surgery, vol.129, no.1, pp.
96–100, 2003.
[ 2 0 ]S .J .M c L e o d ,A .H .Y .L i ,R .L .L e e ,A .E .B u r g e s s ,a n dM .R .
Gold, “The Rap GTPases regulate B cell migration toward the
chemokine stromal cell-derived factor-1 (CXCL12): potential
role for Rap2 in promoting B cell migration,” Journal of
Immunology, vol. 169, no. 3, pp. 1365–1371, 2002.
[21] K. Taira, M. Umikawa, K. Takei et al., “The traf2- and nck-
interacting kinase as a putative eﬀector of Rap2 to regulate
actin cytoskeleton,” The Journal of Biological Chemistry,v o l .
279, no. 47, pp. 49488–49496, 2004.
[22] T. Hirata, H. Nagai, K. Koizumi et al., “Ampliﬁcation, up-
regulation and over-expression of C3G (CRK SH3 domain-
binding guaninenucleotide-releasing factor) in non-smallcell
lung cancers,” Journal of Human Genetics, vol. 49, no. 6, pp.
290–295, 2004.
[23] V. Yajnik, C. Paulding, R. Sordella et al., “DOCK4, a GTPase
activator,isdisruptedduringtumorigenesis,”Cell,vol.112,no.
5, pp. 673–684, 2003.
[24] D. H. Gutmann, S. Saporito-Irwin, J. E. DeClue, R. Wienecke,
and A. Guha, “Alterations in the rap1 signaling pathway are
common in human gliomas,” Oncogene, vol. 15, no. 13, pp.
1611–1616, 1997.
[25] L. Zhang, L. Chenwei, R. Mahmood et al., “Identiﬁcation of a
putative tumor suppressor gene Rap1GAP in pancreatic can-
cer,” Cancer Research, vol. 66, no. 2, pp. 898–906, 2006.
[ 2 6 ]A .N e l l o r e ,K .P a z i a n a ,C .M ae ta l . ,“ L o s so fr a p 1 G A Pi n
papillary thyroid cancer,” Journal of Clinical Endocrinologyand
Metabolism, vol. 94, no. 3, pp. 1026–1032, 2009.
[ 2 7 ]X .D o n g ,C .K o r c h ,a n dJ .L .M e i n k o t h ,“ H i s t o n ed e a c e t y l a s e
inhibitors upregulate Rap1GAP and inhibit Rap activity in
thyroid tumor cells,” Endocrine-Related Cancer, vol. 18, no. 3,
pp. 301–310, 2011.
[ 2 8 ]C .L .B a i l e y ,P .K e l l y ,a n dP .J .C a s e y ,“ A c t i v a t i o no fR a p 1p r o -
motesprostatecancermetastasis,”CancerResearch,vol.69,no.
12, pp. 4962–4968, 2009.
[29] M. Itoh, C. M. Nelson, C. A. Myers, and M. J. Bissell, “Rap1
integrates tissue polarity, lumen formation, and tumorigenic
potential in human breast epithelial cells,” Cancer Research,
vol. 67, no. 10, pp. 4759–4766, 2007.